Why do pharmaceutical companies pay doctors? This question delves into the ethical implications of healthcare, particularly when it comes to the prescription of medications. Imagine you're a cancer patient, and your oncologist prescribes a groundbreaking drug. How much should the pharmaceutical company pay your doctor for this prescription? This is a complex issue that has sparked debates and raised concerns among healthcare professionals and patients alike. In this article, we'll explore the reasons behind these payments, the potential impact on patient care, and the ethical dilemmas it presents. But here's where it gets controversial... The pharmaceutical industry has long used payments to doctors as a form of advertising, offering consultancy fees, advisory board meetings, educational sponsorship, and coverage for travel, accommodation, and entertainment. In 2016, Medicines Australia mandated the reporting of these payments, but it wasn't until a few years later that an online repository was launched to disclose the payments, albeit only for three years from the date of publication and excluding certain categories like food, beverages, and 'research'. During the three years from 2019 to 2022, a significant number of doctors (6,504) received drug company payments, ranging from $30 to $300,000, with a median payment of $1,500. The specialties leading the list in terms of payments were hematology/oncology, cardiology, and endocrinology. Now, let's address the elephant in the room: Why do pharmaceutical companies pay doctors? One explanation is that big business compensates doctors for the time they would otherwise spend earning income elsewhere. Doctors argue that these roles provide 'insider' access to patient drug trials and prescriptions. However, the evidence tells a different story. A systematic review funded by the US National Cancer Institute found a consistent association between drug company payments and increased prescribing of the paying company's drugs, higher prescribing costs, and a preference for branded drugs. Economists suggest that when a drug company pays a doctor, it influences not only the doctor but also their peers. What's more concerning is that these payments lead to increased prescriptions for both recommended and contraindicated patients. When it comes to patient care, it's not clear that doctors with 'access' to drug companies provide better care. In fact, it raises important questions about healthcare ethics. Should doctors stay at arm's length from drug company payments and rely on independent sources of information, or should they view payments as incidental and unrelated to prescribing behavior? Despite the concerns, doctors who refuse to believe that even small gifts like pens and Post-it notes have an insidious impact are the ones most opposed to the idea that drug company payments affect prescribing behavior. This is because, at the end of the day, we are all human and want to reciprocate perceived generosity. The Pharmaceutical Benefits Scheme (PBS) is a taxpayer-funded gift to Australians, but why doesn't the public speak out? It's because doctors maintain enormous trust in society, and these transactions occur outside public scrutiny. As a patient, the thought of my doctor being influenced by anything other than my best interest is unacceptable. However, the truth is that every payment matters. When doctors prescribe unnecessary drugs or suggest more expensive brands, the cost is borne by the taxpayer. Every dollar misspent on health is a dollar not spent on other essential services like housing, education, or transportation. While hospitals and regulators have been cautious, big pharma and individual doctors have exercised their discretion. It's important to clarify that not all interactions are problematic, but what constitutes a problem is highly subjective. Interestingly, when I've written about this topic in the past, I've received feedback from pharmaceutical industry professionals who attest to a problem and report feeling conflicted. I've yet to meet a doctor who accepts money and believes there's no issue. This leads me to believe that the solution to big pharma payments to doctors requires external oversight, as 'physician heal thyself' may not be sufficient. Ranjana Srivastava, an Australian oncologist, award-winning author, and Fulbright scholar, emphasizes the importance of addressing this issue in her book, 'Every Word Matters: Writing to Engage the Public'.
